Spotlight On... Kite and Roche team up in lymphoma; AstraZeneca buys Orexo's respiratory drug; and more...

Kite Pharma ($KITE) is teaming up with Roche's ($RHHBY) Genentech to study its CAR-T cancer therapy in tandem with the checkpoint inhibitor atezolizumab in blood cancer. Under the agreement, Kite and Roche are planning a Phase Ib/II combo study in non-Hodgkin lymphoma, planning to start enrollment this year. Kite's KTE-C19 works by re-engineering patients' own T cells to home in on the cancer antigen CD19, while Roche's in-development atezolizumab is designed to help unblind the immune system to malignancies. The partners believe a combination of the two treatments could have a promising future in a variety of cancer types. News

@FierceBiotech: ICYMI from FierceBiotechResearch: HIV drug increases therapeutic window for skin cancer by slowing drug resistance. Story | Follow @FierceBiotech

@JohnCFierce: As in everything, GSK moves SOOOOO slowly. CEO Witty will leave March, 2017. No rush. | Follow @JohnCFierce

> AstraZeneca ($AZN) has traded $5 million for the full rights to partner Orexo's OX-CLI, a treatment for respiratory disease. More

> Cellectis ($CLLS) partnered with MabQuest to work on antibodies targeting the protein PD-1 to boost the effect of T cells against cancer. Item

Medical Device News

@FierceMedDev: Med tech, healthcare services venture firm HealthQuest raises oversubscribed $225M fund. Story | Follow @FierceMedDev

@VarunSaxena2: The chart is just so darn startling/horrible. (Have mentioned it in stories about opioid abuse-deterrent tech.) More from the NYT | Follow @VarunSaxena2

@EmilyWFierce: 10X Genomics locks down $55M for long-read sequencing tech. News | Follow @EmilyWFierce

> Toshiba sell its medical imaging business to Canon for $6B amid deepening accounting scandal. Report

> Dx Digest: Myriad reveals positive study results for melanoma test; Guardant Health looks to cancer analytics for liquid biopsy. Article

Pharma News

@FiercePharma: India's Lupin hauled up by U.S. FDA for lapses at Goa plant. More from FiercePharmaAsia | Follow @FiercePharma

@CarlyHFierce: Takeda dumps weight loss med Contrave, leaving Orexigen in the lurch. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Chicago psychiatrist slapped with prison time in Teva kickbacks case. More

> GlaxoSmithKline CEO packs his bags for March 2017 exit. Article

CRO News

> INC snags a Quintiles vet as its new science leader. More

> Covance launches mobile health suite for clinical trials. Report

> PDS Life Sciences launches new FDA data compliance service. Story

> Quotient Clinical expands into Japan after PE buyout. Article

Pharma Manufacturing News

> Contract manufacturer PCT will handle TxCell production in U.S. Item

> European drug regulators find lots of plant issues in first quarter. Story

> China's FDA urged to get track-and-trace system in place. Item

> FDA castigates India's Emcure for routinely faking data. Report

> P&G joins Pfizer and Abbott in fighting India's cough med ban. Article

Pharma Asia News

> Chi-Med raises $101.25M in IPO, joining China's BeiGene on Nasdaq. News

> Abbott India unit, others, get court stay on fixed-dose drug bans. Item

> U.S. biotech Quark's siRNA trials include China, India legs. Report

> Nasdaq exec says biotechs prime Asian unicorns for listings. Story

> India's Lupin hauled up by U.S. FDA for lapses at Goa plant. Article

Suggested Articles

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.

Durect's treatment lowered scores that reflect the likelihood a person with alcoholic hepatitis will die within a certain period of time.